Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

A new grant from the UK Academy of Medical Sciences will allow clinicians and scientists from Oxford, Sri Lanka and Thailand to establish new ties to support research into β thalassaemia and benefit those most affected.

Prof Doug Higgs and Dr Sachith Mettananda
Prof Doug Higgs and Dr Sachith Mettananda

β-Thalassaemia is a type of anaemia where a faulty gene leads to misproduction of haemoglobin in red blood cells. No cure is available, except for rare cases where a suitable bone marrow donor can be found. The disease predominantly affects the impoverished communities in the developing world, particularly South and South East Asia.

To develop and support research for new therapies in the areas most affected Dr Sachith Mettananda, a recent graduate from the MRC WIMM and now based at the University of Kelaniya in Sri Lanka, and Prof Doug Higgs (MRC Molecular Haematology Unit, Radcliffe Department of Medicine) successfully applied for a Global Challenges Research Fund Networking Grant, awarded by the UK Academy of Medical Sciences. The researchers plan to use the £25,000 award to fund a series of networking events across the UK, Sri Lanka and Thailand. These will strengthen the existing ties between Sri Lanka and the UK but also establishing a new regional network of researchers and clinicians working on this condition. The award will also help support pilot research in Sri Lanka, in order to build capacity to perform independent genetic therapeutic-based research in this country, with the ultimate aim of providing cutting edge therapies to local patients.

This award is the most recent step in a long history connecting the MRC WIMM to progress in thalassaemia research. Prof Sir David Weatherall, who founded our Institute in 1989, was the first to describe thalassaemia outside the Mediterranean, and over the years our researchers have established the molecular basis of this disease, as well as improved diagnosis and treatment options.

Similar stories

Spin-out company Alethiomics launches

The enterprise will focus on developing targeted therapies for a specific family of blood cancers.

Study links the onset of circulation to changes in metabolism affecting blood stem cell development

A new paper published in Cell Reports by the de Bruijn Group indicates that the onset of circulation triggers a metabolic switch associated with the maturation of haematopoietic stem cells.

Interview with Excellence Award winner Dr Susan Shapiro

A member of the Oxford Centre For Haematology, Dr Shapiro, was recently interviewed by the Royal College of Pathologists.

Mohsin Badat receives ASH-BSH Abstract Achievement Award

Dr Mohsin Badat, a Clinical Training Research Fellow from the Higgs and Davies Groups has been awarded the ASH-BSH Abstract Achievement Award by the American Society of Haematology and the British Society of Haematology.

Iron integral to the development of life on Earth – and the possibility of life on other planets

A collaboration between researchers at the MRC WIMM and Department of Earth Sciences uncovers the importance of iron for the development of complex life on Earth.

Strong cytotoxic T cell responses to an internal viral component are associated with mild COVID-19 disease

Study from the Dong Group reveals key differences in the adaptive immune responses of patients with mild vs. severe COVID-19, highlighting a potential new vaccine target.